1
|
Muraleedharan A, Palappallil DS, Gangadhar R, Das S. Valproate Induced Hyperammonemic Delirium. J Clin Diagn Res 2015; 9:FR01-3. [PMID: 26816916 DOI: 10.7860/jcdr/2015/15562.6883] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Accepted: 10/16/2015] [Indexed: 01/09/2023]
Abstract
Sodium valproate induced hyperammonaemic delirium with normal liver function tests is a relatively uncommon adverse effect. It may be mistaken for psychosis or worsening of mania leading to wrong diagnosis and improper management. Plasma ammonia levels should be monitored in all patients developing altered mental status after receiving valproate therapy. This is a case series of hyperammonaemic delirium due to valproate reported to the Department of Pharmacology from Department of Psychiatry over a period of one year.
Collapse
Affiliation(s)
- Anupama Muraleedharan
- Junior Resident, Department of Pharmacology, Government TDMC , Alappuzha, Kerala, India
| | | | - Reneega Gangadhar
- Professor, Department of Pharmacology, Sree Mookambika Institute of Medical Science , Kulasekharam, Tamil Nadu, India
| | - Soumitra Das
- Junior Resident, Department of Psychiatry, Government TDMC , Alappuzha, Kerala, India
| |
Collapse
|
2
|
Jung BH, Kim BJ, Lee MS, Lee JH, Oh JH, Lee YJ. Dose-dependent pharmacokinetics of toxic metabolites is not related to increased toxicity following high-dose valproic acid in rats. J Appl Toxicol 2010; 30:775-8. [DOI: 10.1002/jat.1608] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
3
|
The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid. Arch Pharm Res 2009; 32:1029-35. [DOI: 10.1007/s12272-009-1708-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2008] [Revised: 06/01/2009] [Accepted: 06/11/2009] [Indexed: 12/18/2022]
|
4
|
Lee MS, Jung BH, Chung BC, Cho SH, Kim KY, Kwon OS, Nugraha B, Lee YJ. Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine. Int J Toxicol 2009; 28:392-404. [PMID: 19605889 DOI: 10.1177/1091581809340329] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Three different doses of valproic acid (20, 100, and 500 mg/kg/d) are administered orally to Sprague-Dawley rats for 5 days, and the feasibility of metabolomics with gas chromatography-mass spectrometry as a predictor of the hepatotoxicity of valproic acid is evaluated. Body weight is found to decrease with the 100-mg/kg/d dose and significantly decrease with the 500-mg/kg/d dose. Mean excreted urine volume is lowest in the 500-mg/kg/d group among all groups. The plasma level of alpha-glutathione-S-transferase, a sensitive and earlier biomarker for hepatotoxicity, increases significantly with administration of 100 and 500 mg/kg/d; however, there is not a significant difference in alpha-glutathione-S-transferase plasma levels between the control and 20-mg/kg/d groups. Clusters in partial least squares discriminant analysis score plots show similar patterns, with changes in physiological conditions and plasma levels of alpha-glutathione-S-transferase; the cluster for the control and 20-mg/kg/d groups does not clearly separate, but the clusters are separate for 100- and 500-mg/kg/d groups. A biomarker of hepatotoxicity, 8-hydroxy-2'-deoxyguanosine and octanoylcarnitine, is identified from nontargeted and targeted metabolic profiling. These results validate that metabolic profiling using gas chromatography-mass spectrometry could be a useful tool for finding novel biomarkers. Thus, a nontargeted metabolic profiling method is established to evaluate the hepatotoxicity of valproic acid and demonstrates proof-of-concept that metabolomic approach with gas chromatography-mass spectrometry has great potential for predicting valproic acid-induced hepatotoxicity and discovering novel biomarkers.
Collapse
Affiliation(s)
- Min Sun Lee
- Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Cheongryang, Seoul, South Korea.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Pradeep RJ. Valproate monotherapy induced-delirium due to hyperammonemia: A report of three adult cases with different types of presentation. Indian J Psychiatry 2008; 50:121-3. [PMID: 19742224 PMCID: PMC2738345 DOI: 10.4103/0019-5545.42400] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
One of the important adverse effects of valproate is delirium due to hyperammonemia. In this case report series, we are reporting three cases with interesting and different types of clinical presentation on valproate monotherapy. Valproate-induced delirium may be mistaken for psychosis or worsening of mania leading to improper diagnosis and poor management. We found that there was an elevated level of plasma ammonia in our cases during the delirious state and which decreased when valproate was discontinued. In our cases the serum valproate levels, liver function tests, electroencephalogram, and imaging studies were normal, which were deranged in the previous case reports. We are the first to rechallenge valproate in one of the cases, to prove that valproate caused the hyperammonemia. We suggest that plasma ammonia levels should be monitored routinely in all cases of altered mental status and receiving valproate therapy.
Collapse
Affiliation(s)
- R Johnson Pradeep
- Senior Resident, Department of Psychiatry, St. John's Medical College and Hospital, Bangalore, India
| |
Collapse
|
6
|
Abstract
The authors present a case of a patient treated with valproic acid for seizure disorder who presented with acute mental status changes consistent with encephalopathy. Notably, her serum ammonia level was 3 times the upper limit of normal, despite an only mildly elevated aspartate aminotransferase and normal bilirubin. Her serum valproic acid level was in the therapeutic range. Her symptoms resolved with discontinuation of valproic acid and supportive care. The authors review the possible mechanisms of valproic acid-associated hyperammonemia with encephalopathy and propose clinical practice modifications to minimize the incidence of this adverse reaction to this generally well-tolerated and clinically important psychotropic medication.
Collapse
Affiliation(s)
- Mariposa McCall
- Department of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center, Sacramento, CA 95817, USA
| | | |
Collapse
|
7
|
Sztajnkrycer MD. Valproic acid toxicity: overview and management. JOURNAL OF TOXICOLOGY. CLINICAL TOXICOLOGY 2002; 40:789-801. [PMID: 12475192 DOI: 10.1081/clt-120014645] [Citation(s) in RCA: 152] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Acute valproic acid intoxication is an increasing problem, accounting for more than 5000 calls to the American Association of Poison Control Centers in 2000. The purpose of this paper is to review the pharmacology and toxicology of valproic acid toxicity. Unlike earlier antiepileptic agents, valproic acid appears to function neither through sodium channel inhibition nor through direct gamma-aminobutyric acid agonism, but through an indirect increase in regional brain gamma-aminobutyric acid levels. Manifestations of acute valproic acid toxicity are myriad, and reflect both exaggerated therapeutic effect and impaired intermediary metabolism. Central nervous system depression is the most common finding noted in overdose, and may progress to coma and respiratory depression. Cerebral edema has also been observed. Although hepatotoxicity is rare in the acute overdose setting, pancreatitis and hyperammonemia have been reported. Metabolic and hematologic derangements have also been described. Management of acute valproic acid ingestion requires supportive care and close attention to the airway. The use of controversial adjunctive therapies, including extracorporeal drug elimination and L-carnitine supplementation, will be discussed.
Collapse
|
8
|
Abstract
The authors report a case of a 41-year-old mentally disabled man with bipolar disorder who presented to the emergency department with altered mental status. He was found to have a significantly elevated ammonia level (377 microM/L) with no signs of hepatic insufficiency. His coma and hyperammonemia were attributed to his chronic valproate therapy. This patient had the highest serum ammonia level ever reported with a therapeutic valproate level in the absence of any other anticonvulsant therapy, metabolic abnormality, or hepatic dysfunction. The authors discuss this case and review the current literature on hyperammonemia in valproic acid therapy and the use of L-carnitine in these patients.
Collapse
Affiliation(s)
- F Barrueto
- Pitt County Memorial Hospital, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
| | | |
Collapse
|
9
|
Kreher U, Darius J, Wien F. Establishing individual metabolite patterns for patients on valproate therapy. Eur J Drug Metab Pharmacokinet 2001; 26:99-107. [PMID: 11554442 DOI: 10.1007/bf03190383] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The aim of this study was to establish individual metabolic profiles of patients receiving valproate (VPA) mono- or polytherapy in order to estimate inter- and intraindividual variability under normal conditions. Serum levels of VPA and 15 metabolites were measured by gas chromotography/mass spectrometry (GC/MS) with selected ion monitoring (SIM). Because of a huge inter-subject variability, calculating means for large epileptic populations resulted in broad and vague ranges for serum levels of VPA and its metabolites. It therefore remained difficult to recognize any significant alteration in the individual metabolic profile. Over long term periods, within-patient changes appeared to be much less intense than inherent interindividual differences. In epileptics consecutively receiving various forms of polytherapy, alterations in the metabolic profiles occurred. Therefore, integrating different kinds of co-medication into a single polytherapy group seemed to be inadequate. An adult patient on VPA monotherapy, suffering form intrahepatic metastasis and renal insufficiency, showed an extremely altered metabolic pattern, with the 4-ene and the omega-/omega1-metabolites being strongly elevated and the major beta-metabolites (E)-2-ene and (E,E)-2,3'-diene being significantly diminished. We suggest determining the individual metabolic profile, consisting of accessible major and minor metabolites, for every patient when VPA therapy has been started or been modified. The moment any clinical complications arise, the previously obtained specific pattern of the individual can be taken as reference in order to assess the possible presance of significant alterations which might indicate or even cause any severe side effects. There seems to be no need of monitoring metabolite levels of the average patient continuously except for the high risk group (e.g. infants under 3 years age receiving polytherapy) which exhibited the highest between-subject as well as within-patient variability.
Collapse
Affiliation(s)
- U Kreher
- Magdeburg University, University Hospital, Department of Clinical Pharmacology, Germany
| | | | | |
Collapse
|
10
|
Warner MH, Anderson GD, McCarty JP, Farwell JR. Effect of carnitine on measures of energy levels, mood, cognition, and sleep in adolescents with epilepsy treated with valproate. ACTA ACUST UNITED AC 1997. [DOI: 10.1016/s0896-6974(97)90004-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Sugimoto T, Muro H, Woo M, Nishida N, Murakami K. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia 1996; 37:1200-3. [PMID: 8956852 DOI: 10.1111/j.1528-1157.1996.tb00553.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
PURPOSE We wished to determine the relation between liver function, beta-, and omega-, and omega-1-oxidation metabolites and 4-en-valproate (VPA). METHODS We measured the serum levels of VPA and its metabolites in children and adolescent receiving high-dose VPA plus phenytoin (PHT) therapy using gas chromatography-mass spectrometry with selected ion monitoring (GC/MS/ SIM). RESULTS In high-dose VPA plus PHT polytherapy, the total VPA serum concentration was distinctly low, the concentrations of total beta-oxidation metabolites were decreased, the percentage values of VPA (percent of VPA) of total beta-oxidation metabolites were increased, and the E-2-en-VPA/3-keto-VPA ratios were decreased, as compared with those in high-dose VPA monotherapy. In high-dose VPA plus PHT polytherapy, 4-en-VPA (microM) was decreased and the concentrations of [omega + (omega-1)]-oxidation metabolites (microM) were decreased as compared with those in high-dose VPA monotherapy. In high-dose VPA plus PHT, serum glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT) and lactic dehydrogenase (LDH) did not correlate significantly with the ¿beta/omega + (omega-1)¿ metabolites ratio and 4-en-VPA levels, but serum GOT, GPT, and LDH were increased as compared with those in high-dose VPA therapy. We were not able to establish a significant relation between the formation of metabolites of VPA metabolites and liver dysfunction in patients receiving high-dose VPA and PHT concurrently. CONCLUSIONS Metabolic levels do not appear to be a reliable predictor of hepatotoxicity in children receiving pharmacological antiepileptic drug (AED) therapy.
Collapse
Affiliation(s)
- T Sugimoto
- Department of Pediatrics, Kansai Medical University Otokoyama Hospital, Kyoto, Japan
| | | | | | | | | |
Collapse
|
12
|
Sugimoto T, Muro H, Woo M, Nishida N, Murakami K. Metabolite profiles in patients on high-dose valproate monotherapy. Epilepsy Res 1996; 25:107-12. [PMID: 8884168 DOI: 10.1016/0920-1211(96)00019-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
To investigate the mechanism of valproate (VPA)-induced hepatotoxicity, we measured the serum and urine metabolites of VPA in high-dose VPA monotherapy by GC/MS/SIM and discussed the relationship between liver function and beta-oxidation, omega-, (omega-1)-oxidation metabolites and 4-en-VPA. In high-dose VPA monotherapy, the concentrations of beta-oxidation metabolites were not increased except for 2-en-VPA, but the concentrations of {omega + (omega-1)}-oxidation metabolites and of 4-en-VPA were increased about 4-5 times compared to those of standard dose VPA monotherapy. Serum GOT was not significantly correlated to 4-en-VPA and the ratio of beta-oxidation/{omega + (omega-1)} oxidation metabolites of VPA in serum. In high-dose VPA monotherapy, it is speculated that the beta-oxidation of VPA in the mitochondria reached the saturation point. However, instead of the beta-oxidation, the {omega + (omega-1)}-oxidation in microsomes was increased. We could not find significant relationship between the formation of toxic metabolites of VPA and liver dysfunction. Our data in VPA monotherapy suggest that the mechanisms of VPA-induced fatal hepatotoxicity cannot be explained by decreased beta-oxidation, increased omega-oxidation and increased 4-en-VPA level.
Collapse
Affiliation(s)
- T Sugimoto
- Department of Pediatrics, Kansai Medical University Otokoyama Hospital, Kyoto, Japan
| | | | | | | | | |
Collapse
|
13
|
Murakami K, Sugimoto T, Woo M, Nishida N, Muro H. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996; 37:687-9. [PMID: 8681902 DOI: 10.1111/j.1528-1157.1996.tb00634.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We analyzed urinary valproate (VPA) metabolites and carnitine concentrations in a child who accidentally ingested 400 mg/kg VPA. The concentration of 4-en VPA, the presumed major factor in VPA-induced hepatotoxicity, was markedly increased, without liver dysfunction or hyperammonemia. The other major abnormality was decreased beta-oxidation and markedly increased omega-oxidation. After L-carnitine supplementation, VPA metabolism returned to normal. The level of valproylcarnitine was not increased and therefore was not affected by L-carnitine. L-Carnitine may be useful in treating patients with coma after VPA overdose.
Collapse
Affiliation(s)
- K Murakami
- Nakano Children's Hospital, Osaka, Japan
| | | | | | | | | |
Collapse
|
14
|
Affiliation(s)
- J H Walter
- Willink Biochemical Genetics Unit, Royal Manchester Children's Hospital, Pendlebury
| |
Collapse
|
15
|
Abstract
The aim of the study was to investigate the effect of carnitine supplementation of valproic acid (VPA) treated patients presenting with increased plasma ammonia concentrations. Plasma ammonia concentrations were recorded in 69 children and young adults on VPA monotherapy (25.6 +/- 9.2 mg VPA/kg per day; mean plasma VPA concentration 68.8 +/- 27.6 mg/l). Their mean plasma ammonia concentration was 80.2 +/- 32.1 micrograms/dl (median 73.1 microgram/dl). A total of 24 patients (35.3%) presenting with ammonia concentrations > 80 microgram/dl were considered hyperammonaemic. Of these, 15/24 (22.1%) showed ammonia concentrations > 100 microgram/dl, even up to 194 micrograms/dl. In 48/69 patients, plasma carnitine concentrations could be determined. The plasma total carnitine (TC) concentrations were rather low (26.9 +/- 8.8 mumol/1) compared to normal values obtained in our laboratory (40.9 +/- 7.2 mumol/1). The percentage of free carnitine was considered decreased (< 75% TC) in 13/48 samples (27%). Fourteen hyperammonaemic patients and one with a plasma ammonia level of 60 micrograms/dl agreed to be supplemented with L-carnitine (1 g/m2 per day divided into two equal doses). Their plasma ammonia and carnitine concentrations were re-evaluated after a mean of 9.1 +/- 4.0 days (median 9.0 days) and in 9 patients again after a mean of 79.6 +/- 30.1 days (median 75 days) of L-carnitine supplementation. Plasma ammonia concentrations decreased in all 15 patients. The decrease was 25.4 +/- 11.2% (median 28.3%) after a mean of 9.1 +/- 4.0 days and amounted to 46.0 +/- 17.2% (median 48%) after 79.6 +/- 30.1 days. L-Carnitine supplementation led to an increase in plasma free carnitine of 11.6 +/- 13.0% (median 15.6%) and to a further increase of 11.1 +/- 8.4% (median 11.5%) when re-evaluated a second time. The plasma ammonia concentrations were significantly correlated with the percentage of free plasma carnitine (r = -0.67; p < 0.0001). The results show that carnitine supplementation is a means of normalizing elevated plasma ammonia concentrations. However, we cannot conclude from our results whether this lowers the risk of developing a VPA-induced Reye's-like syndrome.
Collapse
Affiliation(s)
- H Böhles
- Zentrum der Kinderheilkunde, Johann Wolfgang Goethe-Universität Frankfurt, FRG
| | | | | |
Collapse
|
16
|
Krähenbühl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 1995; 37:140-3. [PMID: 7672665 PMCID: PMC1382786 DOI: 10.1136/gut.37.1.140] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Reduced hepatic mitochondrial beta-oxidation and changes in the plasma carnitine pool are important biochemical findings in valproate induced liver toxicity. The carnitine pools in plasma and liver and the liver coenzyme A (CoA) pool in a patient with fatal, valproate induced hepatotoxicity were measured. In plasma and liver the free and total carnitine contents were decreased, whereas the ratios short chain acylcarnitine/total acid soluble carnitine were increased. The long chain acylcarnitine content was unchanged in plasma, and increased in liver. The total CoA content in liver was decreased by 84%. This was due to reduced concentrations of CoASH, acetyl-CoA, and long chain acyl-CoA whereas the concentrations of succinyl-CoA and propionyl-CoA were both increased. The good agreement between the plasma and liver carnitine pools reflects the close relation between these two pools. The observed decrease in the hepatic CoASH and total CoA content has so far not been reported in humans with valproate induced hepatotoxicity and may be functionally significant.
Collapse
Affiliation(s)
- S Krähenbühl
- Department of Internal Medicine, University Hospital, Zürich, Switzerland
| | | | | | | | | |
Collapse
|
17
|
Averbuch-Heller L, Ben-Hur T, Reches A. Valproate encephalopathy and hypocarnitinaemia in diabetic patients. J Neurol 1994; 241:567-9. [PMID: 7799006 DOI: 10.1007/bf00873521] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Two patients with epilepsy and diabetes mellitus developed encephalopathy while on valproate monotherapy. Low plasma carnitine levels were found. Discontinuation of valproate was followed by clinical recovery and normalization of carnitine levels. Both valproate treatment and diabetes mellitus may contribute to secondary carnitine deficiency, with resultant encephalopathy. Thus, diabetic patients may be at increased risk of developing valproate encephalopathy associated with hypocarnitinaemia.
Collapse
Affiliation(s)
- L Averbuch-Heller
- Department of Neurology, Hadassah University Hospital, Hadassah Medical School, Jerusalem, Israel
| | | | | |
Collapse
|